Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for prevention of antibody-mediated rejection after sensitized living-donor kidney transplant
ACTRN12611000880943Phase 2Recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Mar 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial in kidney allograft rejection comparing Eculizumab with Standard of care (2 arms). Primary endpoints: Primary composite endpoint and Primary analysis timing. Started Mar 2012; status: recruiting.
02
Drugs
eculizumab
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on ACTRN12611000880943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000880943.